HR 3262, the NURSE Act, creates a federal grant program to help schools hire more registered school nurses, primarily targeting public elementary and secondary schools serving high-need communities. The bill prioritizes schools where at least 20% of students qualify for free/reduced-price lunches (indicating high poverty) or lack any nurse, with federal funds covering up to 75% of costs for hiring nurses. Eligible schools or consortia must demonstrate student health needs, such as chronic conditions or mental health support, and the program requires a report to Congress evaluating impacts on nurse staffing and student health outcomes. The grant program is authorized for fiscal years 2026-2030, aiming to address the current shortage where one-third of schools lack a school nurse.
This bill repeals restrictions that previously prevented physicians from owning hospitals, particularly in rural areas. It amends Section 1877 of the Social Security Act to remove specific ownership prohibitions and exceptions related to rural hospitals. The key change allows physicians to directly own or invest in hospitals without needing special qualifying exceptions. This directly affects physicians seeking to own rural hospitals and rural hospitals that previously faced ownership barriers. The bill makes a concrete policy change by removing these legal barriers to physician ownership.
S 1843, the Second Chance Reauthorization Act of 2025, extends funding for existing federal reentry programs through 2030 instead of 2023. It updates timeframes across multiple programs, including state reentry demonstration projects (adding substance use disorder treatment and housing services), family-based substance abuse grants, prison education evaluations, career training for incarcerated individuals, and community mentoring programs. These programs directly support people returning from incarceration by providing critical services like recovery support, job training, and transitional housing. The bill makes no new policy changes but continues current federal funding mechanisms for reentry assistance.
The BABIES Act (S 1598) creates two main programs to expand access to independent birth centers. First, it provides grants of $300,000-$500,000 per year to up to 15 accredited birth centers in underserved areas (e.g., maternity care shortage zones) for facility upgrades, equipment, or accreditation costs ($5 million total over 2026-2030). Second, it launches a Medicaid demonstration program testing new payment models for birth centers serving low-risk pregnant women enrolled in Medicaid, requiring centers to meet strict accreditation, licensure, and care coordination standards. This directly affects birth centers seeking expansion, Medicaid recipients in underserved communities, and states developing payment systems for birth center services.
This bill repeals two specific provisions from the 2023 "Trump Sick Tax Act" (Public Law 119-21) that affected Medicaid and drug pricing. It restores previous Medicaid cost-sharing rules under Title XIX of the Social Security Act and reverts changes to orphan drug exclusions under the Drug Price Negotiation Program (Title XI). These changes directly affect Medicaid beneficiaries and pharmaceutical manufacturers by returning to the pre-2023 policy framework for cost-sharing and drug pricing negotiations. The bill does not create new programs but reverses specific cost-related provisions enacted in 2023.
This bill requires the Secretary of Health and Human Services to issue guidance to state Medicaid programs, CHIPs, and Indian health programs within 12 months of enactment. The guidance focuses on improving syphilis screening for pregnant women (including third trimester and delivery testing), expanding treatment access, educating medical providers and patients, and integrating telehealth services. It directly affects states administering Medicaid/CHIP programs, Indian Health Service, tribes, and urban Indian health organizations by setting best practices for preventing congenital syphilis. The bill mandates a report to Congress within two years analyzing how states implement these guidance recommendations.
This bill amends a Department of Veterans Affairs transportation grant program to improve healthcare access for rural veterans. It expands eligibility to include tribal organizations and Native Hawaiian organizations, and increases grant amounts (up to $50,000, with a potential 50% increase for counties with five or more off-road communities) to cover transportation costs. The changes apply to grants for rural veterans needing transportation to healthcare services, particularly in areas with limited road access. Funding is adjusted from fixed annual amounts to "such sums as may be necessary" for fiscal years 2025-2029.
The Medical Debt Relief Act of 2025 would prevent medical debt from being reported as negative information on credit reports. It defines medical debt as any debt related to medical services, products, or devices and prohibits credit reporting agencies from including such debt - even if sent to collections - in credit reports. The bill also requires the Consumer Financial Protection Bureau to update regulations within one year to ban creditors from using medical debt when making credit decisions. This change directly affects consumers with unpaid medical bills and alters standard credit reporting practices.
This bill, the RARE Act (S 3716), clarifies how orphan drug exclusivity is granted under U.S. law. It changes the definition from "same rare disease or condition" to "same approved use or indication" for determining when a drug can receive 7 years of market exclusivity after approval. This means exclusivity now applies specifically to the drug's approved medical use (e.g., treating a particular symptom or stage of a rare disease), not just the broader disease label. The change directly affects drug manufacturers developing orphan drugs and the FDA's approval process, ensuring exclusivity is tied to specific, approved uses rather than the general disease category. The amendments apply retroactively to all drugs already designated as orphan drugs.
S 1782, the Charlotte Woodward Organ Transplant Discrimination Prevention Act, prohibits hospitals and transplant centers from denying organ transplants or related services solely because of a person’s disability. It requires these covered entities to make reasonable modifications to policies - such as considering a patient’s support network or providing communication aids - to ensure access for qualified individuals with disabilities who meet medical eligibility. The bill allows exceptions only if a physician determines a disability is medically significant to the transplant, but does not permit denial based on inability to independently manage care with available support. This applies to all stages, including evaluation, listing, and post-transplant care, while ensuring it doesn’t override stronger protections under existing disability laws like the ADA.
Tags
People with Disabilities
